Faithanne Hill is not your typical Trinidadian. For one, she loves the beach, which may sound obvious considering she lives on an island, but that is not the case for everyone in Trinidad. “The beach is always there—it never goes away—so most people only go on special occasions or when there’s a holiday,” explained Faith… Continue reading Faith and Ingenuity: Bringing the First Oncology Clinical Trial to Trinidad
Tag: Pediatric Cancer
Researchers uncover what drives aggressive bone cancer
Study identifies a novel mechanism driving osteosarcoma and provides insights to help predict patient outcomes.
Treatment of focal anaplastic Wilms tumor: A report from the Children’s Oncology Group AREN0321 and AREN03B2 studies
Abstract Background In the fifth National Wilms Tumor Study, patients received vincristine and dactinomycin (VA) without radiation for stage I focal anaplastic Wilms tumor (FAWT) and VA plus doxorubicin (DD4A) and radiation for stage II–IV FAWT. Four-year event-free survival (EFS) and overall survival (OS) for stage I FAWT were 67.5% and 88.9% and for stage… Continue reading Treatment of focal anaplastic Wilms tumor: A report from the Children’s Oncology Group AREN0321 and AREN03B2 studies
Hyperleukocytosis in a neuroblastoma patient after treatment with natural killer T cells expressing a GD2-specific chimeric antigen receptor and IL-15
The ability of immune cells to expand numerically after infusion distinguishes adoptive immunotherapies from traditional drugs, providing unique therapeutic advantages as well as the potential for unmanageable toxicities. Here, we describe a case of lethal hyperleukocytosis in a patient with neuroblastoma treated on phase 1 clinical trial (NCT03294954) with autologous natural killer T cells (NKTs)… Continue reading Hyperleukocytosis in a neuroblastoma patient after treatment with natural killer T cells expressing a GD2-specific chimeric antigen receptor and IL-15
From childhood cancer to metabolic syndrome
Cancer, Volume 131, Issue 1, 1 January 2025.
Prevalence and determinants of metabolic syndrome in 2338 childhood cancer survivors: A Dutch Childhood Cancer Survivor LATER 2 study
Abstract Background Because the occurrence of metabolic syndrome (MetS) might contribute to childhood cancer survivor’s excess risk of cardiovascular disease, the authors assessed the prevalence and determinants of MetS in the Dutch Childhood Cancer Survivor Study (DCCSS-LATER2) cohort. Methods In total, 2338 adult childhood cancer survivors (CCS) were cross-sectionally assessed for the prevalence of MetS,… Continue reading Prevalence and determinants of metabolic syndrome in 2338 childhood cancer survivors: A Dutch Childhood Cancer Survivor LATER 2 study
Year in Review: What Themes Emerged in Cancer Research in 2024?
What did we learn about cancer in 2024? How did research advance our understanding of cancer? What new approvals are changing how cancer is being treated? What discoveries could lead to novel treatments down the line? What progress was made in finding ways to detect cancer earlier, closing critical care gaps, and expanding care options… Continue reading Year in Review: What Themes Emerged in Cancer Research in 2024?
Natural lung-tropic TH9 cells: a sharp weapon for established lung metastases
Background Lung metastasis remains the primary cause of tumor-related mortality, with limited treatment options and unsatisfactory efficacy. In preclinical studies, T helper 9 (TH9) cells have shown promise in treating solid tumors. However, it is unclear whether TH9 cells can tackle more challenging situations, such as established lung metastases. Moreover, comprehensive exploration into the nuanced… Continue reading Natural lung-tropic TH9 cells: a sharp weapon for established lung metastases
T-Switch: A specificity-based engineering platform for developing safe and effective T cell therapeutics
Abdelfattah et al. developed an engineering platform (T-Switch) for the creation, modification, and high-throughput profiling of T cell receptors (TCRs) to desired targets, particularly self-antigens. T-Switch identified potent and specific candidate TCRs against a clinically relevant cancer self-target highly expressed in neuroblastoma and has potential for broader application in immunotherapy.
IL-18R supported CAR T cells targeting oncofetal tenascin C for the immunotherapy of pediatric sarcoma and brain tumors
Background Oncofetal splice variants of extracellular matrix (ECM) proteins present a unique group of target antigens for the immunotherapy of pediatric cancers. However, limited data is available if these splice variants can be targeted with T cells expressing chimeric antigen receptors (CARs). Methods To determine the expression of the oncofetal version of tenascin C (TNC)… Continue reading IL-18R supported CAR T cells targeting oncofetal tenascin C for the immunotherapy of pediatric sarcoma and brain tumors